News

Ideas That Generate Results

Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market

Apr 28, 2015

Share |

The much awaited biosimilars have finally entered the US pharmaceutical market with the FDA approval of Sandoz's Zarxio, a G-CSF. The move is expected to make US a significant region for biosimilar activity.

A new research study conducted by RNCOS, "Global Biosimilar Market Outlook 2020", reveals that the market, which was worth US$ 1.89 Billion in 2014, is expected to reach US$ 25.5 Billion by 2020, growing at an impressive CAGR of around 54%. The report has been divided into numerous sections that deal with the various aspects of the market.

The industry has been segmented based on the different classes of biosimilars available in the market, such as, mAbs, Insulin, Erythropoeitin (EPOs), Human Growth Hormone (HGH) and Interferons. The second segmentation divides the industry on the basis of major geographies which includes Europe, Asia-Pacific, and Others (including the US, Latin America and Middle-Eastern countries). The market is subjected to various drivers as well as challenges, which have, and will continue to mould it. The report then talks about the various applications and technological trends that have emerged in the past few years.

The report also highlights key players and their current market share in the biosimilar domain. For every player, a brief business overview, geographic revenue break up, segment wise revenue break up, along with key financials, have been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of the players. At the end, a section has been dedicated to the future outlook. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the biosimilars industry.

Some of the key findings of the report are:

          - Shrinking Healthcare Budgets to Carve Way for Biosimilars
          - Interchangeability to Act as a Major Bottleneck for Biosimilar Adoption

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM742.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm


Media Citation

get in touch

Please fill-in the information below.